PDCD1 and hepatocellular carcinoma: In hepatocellular carcinoma patients, a higher baseline count of PD-L1-high CTCs was associated with a clinical benefit, suggesting the potential use of PD-L1 determination on CTCs to predict the response to anti-PD-1 and anti-PD-L1 monoclonal antibodies [172].